[go: up one dir, main page]

WO2002008260A3 - Bstp-ecg1 protein and related reagents and methods of use thereof - Google Patents

Bstp-ecg1 protein and related reagents and methods of use thereof Download PDF

Info

Publication number
WO2002008260A3
WO2002008260A3 PCT/US2001/023439 US0123439W WO0208260A3 WO 2002008260 A3 WO2002008260 A3 WO 2002008260A3 US 0123439 W US0123439 W US 0123439W WO 0208260 A3 WO0208260 A3 WO 0208260A3
Authority
WO
WIPO (PCT)
Prior art keywords
ecg1
bstp
methods
provides
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/023439
Other languages
French (fr)
Other versions
WO2002008260A9 (en
WO2002008260A2 (en
Inventor
David Botstein
Patrick O Brown
Chuck Perou
Douglas Ross
Rob Seitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Genomics Inc
Leland Stanford Junior University
Original Assignee
Applied Genomics Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genomics Inc, Leland Stanford Junior University filed Critical Applied Genomics Inc
Priority to AU2001278011A priority Critical patent/AU2001278011A1/en
Publication of WO2002008260A2 publication Critical patent/WO2002008260A2/en
Publication of WO2002008260A3 publication Critical patent/WO2002008260A3/en
Anticipated expiration legal-status Critical
Publication of WO2002008260A9 publication Critical patent/WO2002008260A9/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides polypeptides (BSTP-ECG1) and polynucleotides which identify and encode BSTP-ECG1 and fragments and variants thereof. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. In addition, the invention provides methods for treating or preventing disorders of cell proliferation, particularly breast cancer, by administering a pharmaceutical composition comprising a polypeptide, polynucleotide, or antibody of the invention. The invention also provides methods of classifying diseases, particularly breast cancer, by detecting expression of BSTP-ECG1 or of a polynucleotide encoding BSTP-ECG1, and of providing diagnostic, prognostic, and/or predictive information for a patient based on the detection and/or measurement of BSTP-ECG1 or of a polynucleotide encoding BSTP-ECG1.
PCT/US2001/023439 2000-07-26 2001-07-26 Bstp-ecg1 protein and related reagents and methods of use thereof Ceased WO2002008260A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001278011A AU2001278011A1 (en) 2000-07-26 2001-07-26 Bstp-ecg1 protein and related reagents and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22096700P 2000-07-26 2000-07-26
US60/220,967 2000-07-26
US25166900P 2000-12-06 2000-12-06
US60/251,669 2000-12-06

Publications (3)

Publication Number Publication Date
WO2002008260A2 WO2002008260A2 (en) 2002-01-31
WO2002008260A3 true WO2002008260A3 (en) 2002-10-17
WO2002008260A9 WO2002008260A9 (en) 2003-03-20

Family

ID=26915369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023439 Ceased WO2002008260A2 (en) 2000-07-26 2001-07-26 Bstp-ecg1 protein and related reagents and methods of use thereof

Country Status (2)

Country Link
AU (1) AU2001278011A1 (en)
WO (1) WO2002008260A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110489660A (en) * 2019-07-22 2019-11-22 武汉大学 A kind of user's economic situation portrait method of social media public data

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2433992T3 (en) 2002-03-13 2013-12-13 Genomic Health, Inc. Obtaining gene expression profile in biopsied tumor tissues
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US7767391B2 (en) 2003-02-20 2010-08-03 Genomic Health, Inc. Use of intronic RNA to measure gene expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7056674B2 (en) 2003-06-24 2006-06-06 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
JP4906505B2 (en) 2003-07-10 2012-03-28 ジェノミック ヘルス, インコーポレイテッド Expression profile algorithms and tests for cancer diagnosis
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
AU2004309396B2 (en) 2003-12-23 2010-05-13 Genomic Health, Inc. Universal amplification of fragmented RNA
ES2550614T3 (en) 2004-04-09 2015-11-11 Genomic Health, Inc. Gene expression markers to predict the response to chemotherapy
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
JP4939425B2 (en) 2004-11-05 2012-05-23 ジェノミック ヘルス, インコーポレイテッド Molecular indicators of prognosis and prediction of treatment response in breast cancer
CA2585571C (en) 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
EP2016247A4 (en) 2006-05-08 2013-07-17 Canimex Inc BRAKE DEVICE WITH INTEGRATED ANTI-THEFT MECHANISM FOR GARAGE DOORS AND THE LIKE AND DOOR ASSEMBLY INCLUDING THE DEVICE
EP2057177B1 (en) 2006-08-04 2012-11-21 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
AU2016294347B2 (en) 2015-07-10 2022-07-28 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (DGAT2)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044063A2 (en) * 1998-02-25 1999-09-02 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Tumor tissue microarrays for rapid molecular profiling
WO1999047655A2 (en) * 1998-03-20 1999-09-23 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid fragments with heightened expression in normal breast tissue
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044063A2 (en) * 1998-02-25 1999-09-02 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Tumor tissue microarrays for rapid molecular profiling
WO1999047655A2 (en) * 1998-03-20 1999-09-23 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid fragments with heightened expression in normal breast tissue
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CASES S. ET AL.: "Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 42, 19 October 2001 (2001-10-19), October 19, 2001, pages 38870 - 38876, XP002199715, ISSN: 0021-9258 *
GOLUB T. R. ET AL.: "MOLECULAR CLASSIFICATION OF CANCER: CLASS DISCOVERY AND CLASS PREDICTION BY GENE EXPRESSION MONITORING", SCIENCE, vol. 286, 15 October 1999 (1999-10-15), pages 531 - 537, XP002905479, ISSN: 0036-8075 *
MARTIN K. J. ET AL.: "LINKING GENE EXPRESSION PATTERNS TO THERAPEUTIC GROUPS IN BREAST CANCER", CANCER RESEARCH, vol. 60, no. 8, 15 April 2000 (2000-04-15), pages 2232 - 2238, XP001026395, ISSN: 0008-5472 *
MENDOZA L. G. ET AL.: "HIGH-THROUGHPUT MICROARRAY-BASED ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)", BIOTECHNIQUES, vol. 27, no. 4, October 1999 (1999-10-01), pages 778,780,782 - 786,788, XP000992893, ISSN: 0736-6205 *
NACHT M. ET AL.: "Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer", CANCER RESEARCH, vol. 59, no. 21, 1 November 1999 (1999-11-01), pages 5464 - 5470, XP002166291, ISSN: 0008-5472 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110489660A (en) * 2019-07-22 2019-11-22 武汉大学 A kind of user's economic situation portrait method of social media public data
CN110489660B (en) * 2019-07-22 2020-12-18 武汉大学 A method of profiling users' economic status based on social media public data

Also Published As

Publication number Publication date
WO2002008260A9 (en) 2003-03-20
WO2002008260A2 (en) 2002-01-31
AU2001278011A1 (en) 2002-02-05

Similar Documents

Publication Publication Date Title
WO2002008262A3 (en) Bstp-5 proteins and related reagents and methods of use thereof
WO2002008260A3 (en) Bstp-ecg1 protein and related reagents and methods of use thereof
Ye et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine
Hondermarck et al. Proteomics of breast cancer for marker discovery and signal pathway profiling
NZ562192A (en) Use of biomarkers for detecting ovarian cancer
WO2015172843A1 (en) Methods and kits for the diagnosis of cancer
WO2000015793A3 (en) Human gpcr proteins
KR20200028510A (en) Srm assays to chemotherapy targets
WO2002032953A3 (en) Pregnancy-associated plasma protein-a2 (papp-a2)
Petri et al. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology
WO2002008282A3 (en) Bstp-ras/rerg protein and related reagents and methods of use thereof
Ivancic et al. Candidate serum biomarkers for early intestinal cancer using 15N metabolic labeling and quantitative proteomics in the Apc Min/+ mouse
JP2009509169A (en) Biomarkers for prostate cancer
US9261506B2 (en) SRM/MRM assay for subtyping lung histology
Fernández-Grijalva et al. Alpha 2HS-glycoprotein, a tumor-associated antigen (TAA) detected in Mexican patients with early-stage breast cancer
Hong et al. Identification of a specific vimentin isoform that induces an antibody response in pancreatic cancer
WO2005103719A3 (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
AU2015203904A1 (en) SRM assay for PD-L1
EA200000845A1 (en) GENE ENCODING NEW CANCER MARKER
EP1560025A3 (en) Specific markers for diabetes
WO2002008281A3 (en) Bstp-cad protein and related reagents and methods of use thereof
WO2019242741A1 (en) Biomarkers for urothelial carcinoma and applications thereof
KR102356676B1 (en) Biomarkers for diagnosis of pancreatic cancer comprising asprosin, and use thereof
CN112534262A (en) Method for detecting hand-foot-and-mouth disease
WO2000070047A3 (en) Full-length molecules expressed in human tissues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/27-27/27, DRAWINGS, REPLACED BY NEW PAGES 1/27-27/27; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP